RAFAEL CAPARICA BITTON

Índice h a partir de 2011
4
ORCID
Projetos de Pesquisa
Unidades Organizacionais
ICESP-OS, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/24 - Laboratório de Oncologia Experimental, Hospital das Clínicas, Faculdade de Medicina

Filtros

Mostrar mais
Limpar filtros

Configurações

Resultados de Busca

Agora exibindo 1 - 10 de 15
  • article 57 Citação(ões) na Scopus
    Responses to Crizotinib Can Occur in High-Level MET-Amplified Non-Small Cell Lung Cancer Independent of MET Exon 14 Alterations
    (2017) CAPARICA, Rafael; YEN, Cheng Tzu; COUDRY, Renata; IGNATIUS, Sai-Hong; VARELLA-GARCIA, Marileila; CAMIDGE, D. Ross; CASTRO JR., Gilberto de
    Activation of the MET proto-oncogene (MET) highly sensitive to MET inhibition has recently been described in NSCLC through two mechanisms: high-level amplification of the MNNG HOS Transforming gene (MET) (usually expressed relative to the chromosome 7 centromere [CEP7] when using fluorescence in situ hybridization) and exon 14 alterations. As partial overlap of these biomarkers occurs, whether one is purely a surrogate for the other or both can represent true oncogenic driver states continues to be explored. Cases of MET inhibitor-sensitive NSCLC harboring exon 14 alterations without coincident amplification have already been described. Here we report two cases of MET inhibitor-sensitive NSCLC harboring high-level MET amplification (MET/CEP7 ratio >= 5) without coincident exon 14 alterations, suggesting that these two methods of MET activation can produce independent MET-addicted states in NSCLC. Molecular profiling designed to capture all cases of potentially MET-addicted NSCLC should address both activation mechanisms.
  • bookPart
    Câncer de pulmão
    (2016) ROITBERG, Felipe Santa Rosa; BITTON, Rafael Caparica; CASTRO JUNIOR, Gilberto de
  • conferenceObject
    Characterization of EGFR Activating Mutations in Brazilian Patients with Pulmonary Adenocarcinoma
    (2015) YEN, Cheng T.; BITTON, Rafael C.; LIMA, Luiz G. C. A. De; AMADIO, Alex V.; TAKAHASHI, Tiago K.; MARINI, Andrea M.; TAKAGAKI, Tereza Y.; TERRA, Ricardo M.; MELLO, Evandro S.; CASTRO JR., Gilberto De
  • conferenceObject
    Predicting adverse outcomes after cisplatin administration in head & neck and thoracic cancer
    (2013) BITTON, R. C.; CASTRIA, T. B.; AMARAL, A. A.; LOLLO, J. G.; SILVA, V. T. Costa e; BUDMANN, E.; HOFF, P. M.; CASTRO JR., G.
  • article 33 Citação(ões) na Scopus
    The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer
    (2016) PASSIGLIA, Francesco; CAPARICA, Rafael; GIOVANNETTI, Elisa; GIALLOMBARDO, Marco; LISTI, Angela; DIANA, Patrizia; CIRRINCIONE, Girolamo; CAGLEVIC, Christian; RAEZ, Luis E.; RUSSO, Antonio; ROLFO, Christian
    Introduction: Molecular alterations in neurotrophic tyrosine kinase (NTRK) genes have been identified in several solid tumors including lung cancer. Pre-clinical and clinical evidence suggested their potential role as oncogenic drivers and predictive biomarkers for targeted inhibition, leading to the clinical development of a new class of compounds blocking the NTRK molecular pathway, which are currently undner early clinical investigation. Area covered: This review describes the biology of the NTRK pathway and its molecular alterations in lung cancer. It focuses on the pre-clinical and clinical development of emerging NTRK inhibitors, which have shown very promising activity in early phase I studies. Expert opinion: Among the several NTRK-inhibitors, entrectinib and LOXO-101 are those in more advanced stage of clinical development. Both agents have shown encouraging activity along with a tolerable safety profile in patients with different solid tumors harboring NTRK-fusions, emerging as new promising therapeutic options for molecularly selected patients with advanced Trk-driven lung cancers. Results from ongoing phase II basket trials are eagerly awaited.
  • conferenceObject
    Palliative chemotherapy in patients with malignant bowel obstruction
    (2013) MUNIZ, D. Q.; MAK, M. P.; BITTON, R. C.; TAKAHASHI, T. K.; SARAGIOTTO, D. F.; ABDO, E.; SABBAGA, J.; HOFF, P. M.
  • article 5 Citação(ões) na Scopus
    Prophylactic Cranial Irradiation for Extensive-Stage Small-Cell Lung Cancer: A Retrospective Analysis
    (2017) MATUTINO, Adriana; MAK, Milena P.; TAKAHASHI, Tiago K.; BITTON, Rafael C.; NAKAZATO, Denyei; FRAILE, Natalia M. P.; GUIMARAES, Roger G. R.; GABRIELLI, Flavia C. G.; VASCONCELOS, Karina G. M. C.; CARVALHO, Heloisa de A.; CASTRO JR., Gilberto de
    Purpose Extensive-stage small-cell lung cancer (esSCLC) is an incurable disease and represents a therapeutic challenge because of its poor prognosis. Studies in prophylactic cranial irradiation (PCI) in esSCLC have shown a decreased incidence of symptomatic brain metastases in patients who respond to systemic chemotherapy. However, its effect on overall survival is debatable. We evaluated the benefit of PCI in patients with esSCLC in terms of overall survival, progression-free survival, incidence of brain metastases, recurrence rate, and exposure to postrecurrence therapies. Materials and Methods We retrospectively reviewed electronic charts from patients diagnosed with esSCLC from 2008 to 2014 at our institution. All patients had negative baseline brain imaging before chemotherapy and PCI and received at least 4 cycles of platinum-based chemotherapy in the first-line setting without progressive disease on follow-up. PCI was performed at the discretion of the treating physician. Analyses were based on descriptive statistics. Survival curves were calculated by Kaplan-Meier method. Results Among 46 eligible patients, 16 (35%) received PCI and 30 (65%) did not. Compared with no PCI, PCI led to improved progression-free survival (median, 10.32 v 7.66 months; hazard ratio, 0.4521; 95% CI, 0.2481 to 0.8237; P < .001) and overall survival (median, 20.94 v 11.05 months; hazard ratio, 0.2655; 95% CI, 0.1420 to 0.4964; P < .001) as well as lower incidence of brain metastases (19% v 53%; P = .0273) and higher exposure to second-line chemotherapy (87% v 57%; P = .0479). Conclusion Careful patient selection for PCI can improve not only brain metastases control and higher second-line chemotherapy exposure but also patient survival. (c) 2017 by American Society of Clinical Oncology
  • article 17 Citação(ões) na Scopus
    BRAF mutations in non-small cell lung cancer: has finally Janus opened the door?
    (2016) CAPARICA, Rafael; CASTRO JR., Gilberto de; GIL-BAZO, Ignacio; CAGLEVIC, Christian; CALOGERO, Raffaele; GIALLOMBARDO, Marco; SANTOS, Edgardo S.; RAEZ, Luis E.; ROLFO, Christian
    B-Raf mutations occur in about 1-2% of non-small cell lung cancers (NSCLC). These mutations generate a permanent activation of the mitogen activated protein kinase (MAPK) pathway, which promotes tumor growth and proliferation. In the present review, we discuss B-Raf mutation epidemiology, diagnostic methods to detect B-Raf mutations, the role of B-Raf as a driver mutation and a potential therapeutic target in NSCLC. The results of clinical trials involving B-Raf or MAPK pathway inhibitors for the treatment of NSCLC are also discussed. Clinical trials evaluating B-Raf inhibitors in BRAF mutated NSCLC patients have shown promising results, and larger prospective studies are warranted to validate these findings. Enrollment of these patients in clinical trials is an interesting strategy to offer a potentially more effective and less toxic targeted therapy.
  • conferenceObject
    Pulmonary nodules and metastases in non-pulmonary solid tumor bearing patients.
    (2015) VELHO, Pedro Henrique Isaacsson; MAK, Milena Perez; BITTON, Rafael Caparica; ROCHA, Claudio Lima; MOURA, Mauricio Ruettimann Liberato de; VIANA, Publio C. C.; MENEZES, Marcos; FEHER, Olavo
  • conferenceObject
    Pulmonary nodules and metastases in non-pulmonary solid tumor bearing patients
    (2015) VELHO, P. H. Isaacsson; BITTON, R. Caparica; MAK, M. Perez; ROCHA, C. Lima; MOURA, M. Ruettimann Liberato de; VIANA, P. C. C.; MENEZES, M.; FEHER, O.